GAMMA Investing LLC Lowers Position in Sanofi $SNY

GAMMA Investing LLC trimmed its stake in Sanofi (NASDAQ:SNY) by 5.9% in the second quarter, Holdings Channel.com reports. The firm owned 5,701 shares of the company’s stock after selling 356 shares during the quarter. GAMMA Investing LLC’s holdings in Sanofi were worth $275,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in Sanofi during the first quarter valued at approximately $177,831,000. Federated Hermes Inc. lifted its position in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after buying an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC acquired a new position in Sanofi during the first quarter valued at approximately $48,938,000. Raymond James Financial Inc. lifted its position in Sanofi by 15.1% during the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after buying an additional 425,597 shares in the last quarter. Finally, LPL Financial LLC lifted its position in Sanofi by 18.4% during the first quarter. LPL Financial LLC now owns 1,520,721 shares of the company’s stock valued at $84,339,000 after buying an additional 236,625 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Up 1.0%

NASDAQ:SNY opened at $45.54 on Friday. The stock’s 50 day moving average price is $48.27 and its 200 day moving average price is $50.37. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The company has a market capitalization of $111.82 billion, a P/E ratio of 10.95, a P/E/G ratio of 1.07 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter last year, the business earned $1.73 EPS. On average, research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.